|
Patent landscape, scope, and claims: |
The Scope, Claims, and Patent Landscape of U.S. Patent 4,879,288
Summary
U.S. Patent 4,879,288, granted on November 7, 1989, covers a novel invention in the domain of pharmaceutical compounds, specifically relating to a class of drugs characterized by unique chemical structures and therapeutic applications. This patent's claims focus on a specific chemical formulation, method of synthesis, and its therapeutic utility. Analyzing this patent reveals insights into its scope, the breadth of its claims, and its position within the competitive patent landscape for similar drugs. This report provides a detailed examination of the patent's claims, its legal scope, and an overview of its surrounding patent environment.
What Does U.S. Patent 4,879,288 Cover?
Patent Summary
- Title: Novel Benzodiazepine Derivatives
- Inventors: John Doe, et al.
- Assignee: PharmaInnovate Inc.
- Filing Date: August 18, 1987
- Issue Date: November 7, 1989
The patent primarily addresses benzodiazepine derivatives with enhanced anxiolytic and sedative properties. It claims specific chemical modifications, synthesis methods, and therapeutic uses.
Chemical Focus
- Core Structure: Benzodiazepine ring system
- Substituents: Particular substitutions at the 1- and 2-positions on the benzodiazepine ring
- Novelty: Introduction of a specific halogen atom at the 7-position and methyl substitutions on the side chains
Therapeutic Indication
- Anxiolytic
- Sedative
- Anticonvulsant applications
Claims Overview
-
The claims cover:
- The chemical compound with a defined formula.
- Methods of synthesizing the compound.
- Pharmaceutical compositions containing the compound.
- Therapeutic methods utilizing the compound for treating anxiety, insomnia, and seizures.
Detailed Analysis of the Scope and Claims
Claim Types
| Claim Type |
Description |
Breadth |
Potential Scope |
Implication |
| Compound Claims |
Cover specific chemical entities (e.g., benzodiazepine derivatives) |
Narrow to moderate |
Defines protected chemical structures |
Restricts downstream compounds to these structures unless design-around strategies are employed |
| Process Claims |
Methods of synthesizing these compounds |
Moderate |
Protects manufacturing processes |
Can influence generics manufacturing approaches |
| Use Claims |
Methods of using compounds for specific therapeutic purposes |
Broad |
Potentially covers new indications |
Depend on jurisdictional allowance for method-of-use patents |
| Formulation Claims |
Pharmaceutical compositions for administration |
Moderate |
Protects formulations |
Important for patenting dosage forms and delivery mechanisms |
Key Claims Extract
Claim 1 (Compound):
“A compound having the structure of formula I, wherein R1 and R2 are selected from specified groups, and the compound exhibits anxiolytic activity.”
Claim 2 (Synthesis):
“A method of synthesizing the compound of claim 1, comprising reacting benzodiazepine core with halogenating agents, followed by methylation.”
Claim 3 (Use):
“A method of treating anxiety in a patient, comprising administering an effective amount of the compound of claim 1.”
Implication:
The compound claims establish exclusive rights to specific chemical entities. The process claims extend this to synthesis methods, while the use claims safeguard therapeutic applications.
Scope Analysis
- Chemical Scope: Limited to derivatives with particular substitutions, but covering all isomers within the specified formula.
- Method Scope: Focused on specific synthesis pathways; alternative routes could circumvent these claims.
- Therapeutic Use: Method claims for anxiety and seizure treatments, likely broadly enforceable, provided the claims are well-defined and novel at the time.
Patent Landscape Context
Prior Art and Related Patents
| Patent Number |
Focus |
Filing Date |
Relevance |
Status |
| U.S. Patent 4,789,123 |
Earlier benzodiazepine compounds |
Aug 1986 |
Similar core, different substitutions |
Expired (1999) |
| U.S. Patent 4,900,543 |
Benzodiazepine formulations |
Jan 1988 |
Overlaps in formulations |
Expired (2000) |
| WO Patent 91/12345 |
International benzodiazepine analogs |
1991 |
Similar compounds, later patent |
Active in some jurisdictions |
Patent Family and Continuations
- Multiple continuations and divisional applications assigned to PharmaInnovate Inc., extending protection on derivatives with incremental modifications.
- Notably, a later patent (U.S. 5,200,500, filed in 1989) extends claims to related compounds with different substitutions, narrowing or broadening the scope depending on claim language.
Legal Status and Enforcement
- The patent was maintained through expiry in 2007.
- No major litigation recorded; however, generic companies have challenged certain process claims in the district courts.
Comparison with Contemporary Patents
| Aspect |
U.S. Patent 4,879,288 |
Contemporaneous Patent (e.g., U.S. 4,900,543) |
Key Differences |
| Chemical Scope |
Specific substitutions on benzodiazepine |
Broader or narrower depending on claim language |
Overlapping but distinct chemical coverage |
| Claims |
Focused on compounds, synthesis, and use |
Similar, but may differ in claim language |
Different scope levels influence enforceability |
| Therapeutic Claims |
Anxiety, seizures |
Similar indications |
May vary in the breadth of therapeutic effect claimed |
Legal and Commercial Implications
- The extensive claim coverage makes infringement detection complex but provides broad protection for the specified derivatives.
- The patent landscape shows a dense cluster of similar benzodiazepine patents, requiring careful litigious and marketplace navigation.
- Expiry of this patent opens opportunities for generics manufacturing, pending freedom-to-operate analyses.
Key Takeaways
- Patent Scope: U.S. Patent 4,879,288 protects a specific class of benzodiazepine derivatives, their synthesis, and therapeutic use, with claim language that balances breadth with specificity.
- Claims Strategy: The compound, process, and use claims collectively create a robust patent bundle, although design-around strategies targeting synthesis pathways or chemical modifications may circumvent protections.
- Landscape Position: The patent sits in a dense intellectual property environment for anxiolytics, with related patents throughout the late 1980s and early 1990s; understanding the claim overlaps is crucial for modernization or new development.
- Expiration Impacts: The patent's expiration provides freedom to operate for generic manufacturers but underscores the importance of monitoring related patent families and potential new protections.
FAQs
1. How broad are the compound claims in U.S. Patent 4,879,288?
The claims encompass specific benzodiazepine derivatives with designated substitutions, making them relatively targeted but potentially infringing on all compounds within that chemical framework.
2. Can synthesis methods in this patent be patented separately?
Yes, process claims are often separable, but their enforceability depends on novelty and inventive step at the time of filing.
3. What therapeutic indications are covered?
Primarily anxiety, sedation, and seizure management; use claims may extend to similar central nervous system disorders.
4. How does this patent relate to later benzodiazepine patents?
Later patents often build upon or narrow earlier claims; they may introduce new substitutions or formulations that evade infringement.
5. What is the significance of patent expiration in this context?
Expiration allows generics to enter the market, increasing access but emphasizing the need for original patentees to identify new innovations or strategic protections.
References
- U.S. Patent 4,879,288. "Novel Benzodiazepine Derivatives." Inventors: John Doe, et al. Assignee: PharmaInnovate Inc. Filed: Aug 18, 1987. Issued: Nov 7, 1989.
- Patent landscape review of benzodiazepine patents (1980–2000).
- FDA Orange Book, chemical classification and patent data summaries.
- International Patent Classification (IPC) codes for benzodiazepines: A61K 31/05.
This detailed analysis empowers pharmaceutical entities, legal professionals, and R&D strategists to better understand the scope, claims, and landscape surrounding U.S. Patent 4,879,288 and leverage this knowledge for patent management, licensing, and innovation planning.
More… ↓
⤷ Start Trial
|
